Systolic Blood Pressure, Cardiovascular Mortality, and All-Cause Mortality in Normoglycemia, Prediabetes, and Diabetes.
diabetes mellitus
mortality
normoglycemia
prediabetes
systolic blood pressure
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
05
2020
accepted:
09
06
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
6
8
2020
Statut:
epublish
Résumé
The optimal blood pressure (BP) level for diabetic patients remains controversial, while studies provided limited evidence on BP management for individuals with normoglycemia or prediabetes. We aimed to investigate the associations between systolic blood pressure (SBP) and all-cause and cardiovascular (CVD) mortality among US adults with different glycemic profiles. We used data from the 1999-2014 National Health and Nutrition Examination Survey (NHANES, n=40,046) with comprehensive baseline examination and follow-up assessment. Restricted cubic spline analysis was performed to examine dose-response relationship between SBP and mortality risk. Cox regression models were used to estimate hazard ratios of all-cause mortality and CVD mortality for SBP categories. U-shaped associations between SBP and all-cause mortality were observed regardless of glucose status. The relationship between SBP and CVD mortality was found to be U-shaped only in normoglycemic participants. The lowest mortality risk of optimal SBP (mmHg) by group was 115-120 (normoglycemia), 120-130 (prediabetes), and 125-135 (diabetes). When compared with the reference group, SBP < 100 mmHg was significantly associated with 49% (HR=1.49, 95% CI: 1.13-1.96), 57% (1.57, 1.07-2.3), and 59% (1.59, 1.12-2.25) higher all-cause mortality risk in people with normoglycemia, prediabetes, and diabetes, respectively. The multivariable-adjusted HRs of all-cause mortality for SBP ≥150 mmHg were 1.51 (1.25-1.82), 1.56 (1.27-1.93), and 1.33 (1.08-1.64), respectively. As for CVD mortality, the multivariable-adjusted HRs were 2.85 (1.29-6.33) for SBP <100 mmHg and 2.71 (1.56-4.69) for SBP ≥150 mmHg in normoglycemia; HR was 1.66 (1.05-2.63) for SBP ≥150 mmHg in diabetic patients. U-shaped relationships between SBP and all-cause mortality were observed regardless of diabetes status. The optimal SBP range was gradually higher with worsening glucose status.
Sections du résumé
BACKGROUND
BACKGROUND
The optimal blood pressure (BP) level for diabetic patients remains controversial, while studies provided limited evidence on BP management for individuals with normoglycemia or prediabetes. We aimed to investigate the associations between systolic blood pressure (SBP) and all-cause and cardiovascular (CVD) mortality among US adults with different glycemic profiles.
METHODS
METHODS
We used data from the 1999-2014 National Health and Nutrition Examination Survey (NHANES, n=40,046) with comprehensive baseline examination and follow-up assessment. Restricted cubic spline analysis was performed to examine dose-response relationship between SBP and mortality risk. Cox regression models were used to estimate hazard ratios of all-cause mortality and CVD mortality for SBP categories.
RESULTS
RESULTS
U-shaped associations between SBP and all-cause mortality were observed regardless of glucose status. The relationship between SBP and CVD mortality was found to be U-shaped only in normoglycemic participants. The lowest mortality risk of optimal SBP (mmHg) by group was 115-120 (normoglycemia), 120-130 (prediabetes), and 125-135 (diabetes). When compared with the reference group, SBP < 100 mmHg was significantly associated with 49% (HR=1.49, 95% CI: 1.13-1.96), 57% (1.57, 1.07-2.3), and 59% (1.59, 1.12-2.25) higher all-cause mortality risk in people with normoglycemia, prediabetes, and diabetes, respectively. The multivariable-adjusted HRs of all-cause mortality for SBP ≥150 mmHg were 1.51 (1.25-1.82), 1.56 (1.27-1.93), and 1.33 (1.08-1.64), respectively. As for CVD mortality, the multivariable-adjusted HRs were 2.85 (1.29-6.33) for SBP <100 mmHg and 2.71 (1.56-4.69) for SBP ≥150 mmHg in normoglycemia; HR was 1.66 (1.05-2.63) for SBP ≥150 mmHg in diabetic patients.
CONCLUSION
CONCLUSIONS
U-shaped relationships between SBP and all-cause mortality were observed regardless of diabetes status. The optimal SBP range was gradually higher with worsening glucose status.
Identifiants
pubmed: 32753922
doi: 10.2147/DMSO.S260990
pii: 260990
pmc: PMC7352464
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2375-2388Informations de copyright
© 2020 Chen et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest in this work.
Références
Lancet. 2016 Oct 29;388(10056):2142-2152
pubmed: 27590221
Diabetologia. 2013 Jul;56(7):1489-93
pubmed: 23584433
Diabetes Care. 1993 Feb;16(2):434-44
pubmed: 8432214
Ann Intern Med. 2015 Dec 1;163(11):861-8
pubmed: 26501513
Curr Hypertens Rep. 2012 Dec;14(6):556-66
pubmed: 23054894
Diabetes Care. 2020 Apr;43(4):894-902
pubmed: 32054721
Diabetes Care. 2013 Aug;36(8):2286-93
pubmed: 23603918
Diabetes Care. 2017 Apr;40(4):453-460
pubmed: 28223299
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Diabetes Care. 2018 Sep;41(9):1895-1900
pubmed: 30002198
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
Diabetes Educ. 2017 Apr;43(2):151
pubmed: 28340543
Lancet. 2016 Mar 5;387(10022):957-967
pubmed: 26724178
Lancet. 2011 Jul 2;378(9785):31-40
pubmed: 21705069
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
BMJ. 2016 Aug 04;354:i4070
pubmed: 27492939
Lancet Diabetes Endocrinol. 2018 May;6(5):392-403
pubmed: 29500121
N Engl J Med. 2010 Apr 29;362(17):1575-85
pubmed: 20228401
JAMA. 2010 Jul 7;304(1):61-8
pubmed: 20606150
BMJ. 2016 Nov 23;355:i5953
pubmed: 27881363
JAMA Cardiol. 2017 Jul 1;2(7):775-781
pubmed: 28564682
Diabetes Care. 2019 Dec;42(12):2322-2329
pubmed: 31591089
Hypertension. 2018 Jun;71(6):1039-1046
pubmed: 29669793
Diabetes Res Clin Pract. 2007 Dec;78(3):305-12
pubmed: 17601626
J Hypertens. 2017 May;35(5):922-944
pubmed: 28141660
Circulation. 2011 Jun 21;123(24):2799-810, 9 p following 810
pubmed: 21632497
JAMA Intern Med. 2019 Dec 30;:
pubmed: 31886824
J Hypertens. 2011 Jul;29(7):1253-69
pubmed: 21505352
J Hypertens. 2009 Nov;27(11):2121-58
pubmed: 19838131
Diabetes Care. 2017 Aug 9;:
pubmed: 28793997
N Engl J Med. 2001 May 3;344(18):1343-50
pubmed: 11333990
Hypertension. 2020 Feb;75(2):331-338
pubmed: 31865790
J Hum Hypertens. 2017 Nov;31(11):744-749
pubmed: 28748918
BMJ. 2016 Feb 24;352:i717
pubmed: 26920333
Diabet Med. 2017 Jan;34(1):69-78
pubmed: 26606421
J Hypertens. 2013 Aug;31(8):1603-10
pubmed: 23625112
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Hypertension. 2015 Mar;65(3):525-30
pubmed: 25624343
Int J Cardiol. 2016 Mar 1;206:116-21
pubmed: 26788685
Lancet. 2016 Jan 30;387(10017):435-43
pubmed: 26559744
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272